28936-94-9 Usage
Description
8-Benzyl-1,3,8-triazaspiro[4.5]decane-2,4-dione is an organic compound characterized by its unique spirocyclic structure, which consists of a triazole and a spiro-linked decane dione. 8-BENZYL-1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONE is known for its potential applications in the field of organic chemistry, particularly in the synthesis of various heterocyclic compounds.
Uses
Used in Organic Chemistry Research:
8-Benzyl-1,3,8-triazaspiro[4.5]decane-2,4-dione is used as a research reagent for the synthesis of spirohydantoins from basic heterocyclic ketones. Its unique structure allows for the creation of novel compounds with potential applications in various fields, such as pharmaceuticals, agrochemicals, and materials science.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 8-Benzyl-1,3,8-triazaspiro[4.5]decane-2,4-dione is used as a key intermediate in the synthesis of various drug candidates. Its ability to form spirohydantoins makes it a valuable building block for the development of new medications with potential therapeutic applications.
Used in Agrochemical Industry:
8-Benzyl-1,3,8-triazaspiro[4.5]decane-2,4-dione is also utilized in the agrochemical industry for the development of new pesticides and other crop protection agents. Its unique structure can be exploited to create novel compounds with improved efficacy and selectivity, contributing to more sustainable agricultural practices.
Used in Materials Science:
In the field of materials science, 8-Benzyl-1,3,8-triazaspiro[4.5]decane-2,4-dione can be used as a component in the development of advanced materials with specific properties, such as improved mechanical strength, thermal stability, or chemical resistance. Its incorporation into polymers or other materials can lead to the creation of innovative products with a wide range of applications.
Check Digit Verification of cas no
The CAS Registry Mumber 28936-94-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,9,3 and 6 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 28936-94:
(7*2)+(6*8)+(5*9)+(4*3)+(3*6)+(2*9)+(1*4)=159
159 % 10 = 9
So 28936-94-9 is a valid CAS Registry Number.
InChI:InChI=1/C14H17N3O2/c18-12-14(16-13(19)15-12)6-8-17(9-7-14)10-11-4-2-1-3-5-11/h1-5H,6-10H2,(H2,15,16,18,19)
28936-94-9Relevant articles and documents
PROGRANULIN MODULATORS AND METHODS OF USING THE SAME
-
Paragraph 0400, (2021/04/30)
Provided herein are compounds of formula (I) that modulate progranulin and methods of using the compounds in progranulin- associated disorders, such as Frontotemperal lobe dementia (FTLD).
Opioid receptor agonists and application thereof
-
Paragraph 1683; 1686-1691, (2019/01/24)
The invention discloses compounds and salts thereof that can be used as opioid receptor ligands, a preparation method of the compounds, compositions containing the compounds, and a use of the compounds as [mu] opioid receptor agonists; the compounds are used for treatment of [mu] opioid receptor-mediated related diseases, such as pains and pain-related disorders.
Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19
Mallinger, Aurélie,Schiemann, Kai,Rink, Christian,Stieber, Frank,Calderini, Michel,Crumpler, Simon,Stubbs, Mark,Adeniji-Popoola, Olajumoke,Poeschke, Oliver,Busch, Michael,Czodrowski, Paul,Musil, Djordje,Schwarz, Daniel,Ortiz-Ruiz, Maria-Jesus,Schneider, Richard,Thai, Ching,Valenti, Melanie,De Haven Brandon, Alexis,Burke, Rosemary,Workman, Paul,Dale, Trevor,Wienke, Dirk,Clarke, Paul A.,Esdar, Christina,Raynaud, Florence I.,Eccles, Suzanne A.,Rohdich, Felix,Blagg, Julian
supporting information, p. 1078 - 1101 (2016/02/23)
The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in human disease, particularly in colorectal cancer where it has been reported as a putative oncogene. Here we report the discovery of 109 (CCT251921), a potent, selective, and orally bioavailable inhibitor of CDK8 with equipotent affinity for CDK19. We describe a structure-based design approach leading to the discovery of a 3,4,5-trisubstituted-2-aminopyridine series and present the application of physicochemical property analyses to successfully reduce in vivo metabolic clearance, minimize transporter-mediated biliary elimination while maintaining acceptable aqueous solubility. Compound 109 affords the optimal compromise of in vitro biochemical, pharmacokinetic, and physicochemical properties and is suitable for progression to animal models of cancer.